Key result
Statin therapy is linked to attenuated LVEF decline during trastuzumab treatment for breast cancer.
Why the study?
The association between statin use and changes in LVEF during trastuzumab therapy in women with breast cancer was unclear.
Does statin use attenuate left ventricular ejection fraction decline in female patients with breast cancer receiving trastuzumab?
Observational (n=215)
Yes
Does statin use attenuate left ventricular ejection fraction decline in female patients with breast cancer receiving trastuzumab?
In women receiving trastuzumab for breast cancer, statin use is associated with better preservation of left ventricular ejection fraction at 12 months, suggesting a potential cardioprotective effect.
Answers are grounded in this paper and cite their sources.
Statin use should not yet change practice in trastuzumab recipients; leaves open a cardioprotective hypothesis for randomized confirmation.
Aims We examined the association between statin use and changes in left ventricular ejection fraction (LVEF) during trastuzumab therapy in women with breast cancer. Methods: This post-hoc analysis of the CHECK HEART-BC study included 215 patients with normal baseline LVEF and 12-month echocardiographic follow-up. We assessed LVEF at baseline and at 3, 6, 9, and 12 months by statin use. Results Of 215 women, 31 (14%) were receiving statins. Baseline LVEF was comparable between groups. After a similar decline at 3 months, LVEF trajectories diverged, with better preservation among statin users apparent at 9 months and most pronounced at 12 months. Statin use was associated with attenuated LVEF decline over time in an adjusted longitudinal model (interaction estimate, 0.27; standard error, 0.10; P = 0.005). Conclusions Statin use was associated with better LVEF preservation during trastuzumab therapy, particularly during later follow-up. These findings are hypothesis generating and require confirmation in randomized trials.
No takes yet. Share an insight, caveat, or question.
Nochioka et al. (2026) conducted an observational in Breast cancer (n=215). Statin use vs. No statin use was evaluated on Longitudinal changes in left ventricular ejection fraction (LVEF) (interaction estimate 0.27, p=0.005). Statin use was associated with an attenuated decline in left ventricular ejection fraction over 12 months in women with breast cancer receiving trastuzumab therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: